Unrest Highlights Low Investor Sentiment

BMI View: While a plunge in Hikma Pharmaceuticals' share price has shown developments across Tunisia, Egypt, Libya and other markets in the Middle East and North Africa (MENA) region to be a blow to investor sentiment, BMI's pharmaceuticals and healthcare team remains bullish on the company's long-term performance. This optimistic outlook is based on its overall strategy and strong focus on generic medicines. A strong five-year growth forecast in pharmaceutical markets across the region (which accounted for 68% of the company's revenues in H110), is expected to provide the company with significant revenue-earning

To read the full article, please choose one of the following options: